Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer

Stavroula Sofou, Richard Enmon, Stig Palm, Barry Kappel, Pat Zanzonico, Michael R. McDevitt, David A. Scheinberg, George Sgouros

Research output: Contribution to journalArticle

Abstract

Effective targeting and killing of intraperitoneally disseminated micrometastases remains a challenge. Objective/Methods:In this work, we evaluated the potential of antibody-labeled PEGylated large liposomes as vehicles for direct intraperitoneal (i.p.) drug delivery with the aim to enhance the tumor-to-normal organ ratio and to improve the bioexposure of cancer cells to the delivered therapeutics while shifting the toxicities toward the spleen. These targeted liposomes are designed to combine: (1) specific targeting to and internalization by cancer cells mediated by liposome-conjugated tumor-specific antibodies, (2) slow clearance from the peritoneal cavity, and (3) shift of normal organ toxicities from the liver to the spleen due to their relatively large size. Results:Conjugation of anti-HER2/neu antibodies to the surface of large (approximately 600nm in diameter) PEGylated liposomes results in fast, specific binding of targeted liposomes to cancer cells in vitro, followed by considerable cellular internalization. In vivo, after i.p. administration, these liposomes exhibit fast, specific binding to i.p. cancerous tumors. Large liposomes are slowly cleared from the peritoneal cavity, and they exhibit increased uptake by the spleen relative to the liver, while targeted large liposomes demonstrate specific tumor uptake at early times. Although tissue and tumor uptake are greater for cationic liposomes, the tumor-to-liver and spleen-to-liver ratios are similar for both membrane compositions, suggesting a primary role for the liposome's size, compared to the liposome's surface charge. Conclusions:The findings of this study suggest that large targeted liposomes administered i.p. could be a potent drug-delivery strategy for locoregional therapy of i.p. micrometastatic tumors.

Original languageEnglish (US)
Pages (from-to)330-340
Number of pages11
JournalJournal of Liposome Research
Volume20
Issue number4
DOIs
StatePublished - Dec 2010

Fingerprint

Liposomes
Neoplasms
Therapeutics
Spleen
Liver
Peritoneal Cavity
Neoplasm Antibodies
Neoplasm Micrometastasis
Antibodies
Pharmaceutical Preparations
Membranes

Keywords

  • Intraperitoneal therapy
  • Large liposomes
  • Ovarian cancer
  • Targeted liposomes
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. / Sofou, Stavroula; Enmon, Richard; Palm, Stig; Kappel, Barry; Zanzonico, Pat; McDevitt, Michael R.; Scheinberg, David A.; Sgouros, George.

In: Journal of Liposome Research, Vol. 20, No. 4, 12.2010, p. 330-340.

Research output: Contribution to journalArticle

Sofou, S, Enmon, R, Palm, S, Kappel, B, Zanzonico, P, McDevitt, MR, Scheinberg, DA & Sgouros, G 2010, 'Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer', Journal of Liposome Research, vol. 20, no. 4, pp. 330-340. https://doi.org/10.3109/08982100903544185
Sofou, Stavroula ; Enmon, Richard ; Palm, Stig ; Kappel, Barry ; Zanzonico, Pat ; McDevitt, Michael R. ; Scheinberg, David A. ; Sgouros, George. / Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. In: Journal of Liposome Research. 2010 ; Vol. 20, No. 4. pp. 330-340.
@article{61bd9c19efe542b78cb67f4ac2c0b8ff,
title = "Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer",
abstract = "Effective targeting and killing of intraperitoneally disseminated micrometastases remains a challenge. Objective/Methods:In this work, we evaluated the potential of antibody-labeled PEGylated large liposomes as vehicles for direct intraperitoneal (i.p.) drug delivery with the aim to enhance the tumor-to-normal organ ratio and to improve the bioexposure of cancer cells to the delivered therapeutics while shifting the toxicities toward the spleen. These targeted liposomes are designed to combine: (1) specific targeting to and internalization by cancer cells mediated by liposome-conjugated tumor-specific antibodies, (2) slow clearance from the peritoneal cavity, and (3) shift of normal organ toxicities from the liver to the spleen due to their relatively large size. Results:Conjugation of anti-HER2/neu antibodies to the surface of large (approximately 600nm in diameter) PEGylated liposomes results in fast, specific binding of targeted liposomes to cancer cells in vitro, followed by considerable cellular internalization. In vivo, after i.p. administration, these liposomes exhibit fast, specific binding to i.p. cancerous tumors. Large liposomes are slowly cleared from the peritoneal cavity, and they exhibit increased uptake by the spleen relative to the liver, while targeted large liposomes demonstrate specific tumor uptake at early times. Although tissue and tumor uptake are greater for cationic liposomes, the tumor-to-liver and spleen-to-liver ratios are similar for both membrane compositions, suggesting a primary role for the liposome's size, compared to the liposome's surface charge. Conclusions:The findings of this study suggest that large targeted liposomes administered i.p. could be a potent drug-delivery strategy for locoregional therapy of i.p. micrometastatic tumors.",
keywords = "Intraperitoneal therapy, Large liposomes, Ovarian cancer, Targeted liposomes, Trastuzumab",
author = "Stavroula Sofou and Richard Enmon and Stig Palm and Barry Kappel and Pat Zanzonico and McDevitt, {Michael R.} and Scheinberg, {David A.} and George Sgouros",
year = "2010",
month = "12",
doi = "10.3109/08982100903544185",
language = "English (US)",
volume = "20",
pages = "330--340",
journal = "Journal of Liposome Research",
issn = "0898-2104",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer

AU - Sofou, Stavroula

AU - Enmon, Richard

AU - Palm, Stig

AU - Kappel, Barry

AU - Zanzonico, Pat

AU - McDevitt, Michael R.

AU - Scheinberg, David A.

AU - Sgouros, George

PY - 2010/12

Y1 - 2010/12

N2 - Effective targeting and killing of intraperitoneally disseminated micrometastases remains a challenge. Objective/Methods:In this work, we evaluated the potential of antibody-labeled PEGylated large liposomes as vehicles for direct intraperitoneal (i.p.) drug delivery with the aim to enhance the tumor-to-normal organ ratio and to improve the bioexposure of cancer cells to the delivered therapeutics while shifting the toxicities toward the spleen. These targeted liposomes are designed to combine: (1) specific targeting to and internalization by cancer cells mediated by liposome-conjugated tumor-specific antibodies, (2) slow clearance from the peritoneal cavity, and (3) shift of normal organ toxicities from the liver to the spleen due to their relatively large size. Results:Conjugation of anti-HER2/neu antibodies to the surface of large (approximately 600nm in diameter) PEGylated liposomes results in fast, specific binding of targeted liposomes to cancer cells in vitro, followed by considerable cellular internalization. In vivo, after i.p. administration, these liposomes exhibit fast, specific binding to i.p. cancerous tumors. Large liposomes are slowly cleared from the peritoneal cavity, and they exhibit increased uptake by the spleen relative to the liver, while targeted large liposomes demonstrate specific tumor uptake at early times. Although tissue and tumor uptake are greater for cationic liposomes, the tumor-to-liver and spleen-to-liver ratios are similar for both membrane compositions, suggesting a primary role for the liposome's size, compared to the liposome's surface charge. Conclusions:The findings of this study suggest that large targeted liposomes administered i.p. could be a potent drug-delivery strategy for locoregional therapy of i.p. micrometastatic tumors.

AB - Effective targeting and killing of intraperitoneally disseminated micrometastases remains a challenge. Objective/Methods:In this work, we evaluated the potential of antibody-labeled PEGylated large liposomes as vehicles for direct intraperitoneal (i.p.) drug delivery with the aim to enhance the tumor-to-normal organ ratio and to improve the bioexposure of cancer cells to the delivered therapeutics while shifting the toxicities toward the spleen. These targeted liposomes are designed to combine: (1) specific targeting to and internalization by cancer cells mediated by liposome-conjugated tumor-specific antibodies, (2) slow clearance from the peritoneal cavity, and (3) shift of normal organ toxicities from the liver to the spleen due to their relatively large size. Results:Conjugation of anti-HER2/neu antibodies to the surface of large (approximately 600nm in diameter) PEGylated liposomes results in fast, specific binding of targeted liposomes to cancer cells in vitro, followed by considerable cellular internalization. In vivo, after i.p. administration, these liposomes exhibit fast, specific binding to i.p. cancerous tumors. Large liposomes are slowly cleared from the peritoneal cavity, and they exhibit increased uptake by the spleen relative to the liver, while targeted large liposomes demonstrate specific tumor uptake at early times. Although tissue and tumor uptake are greater for cationic liposomes, the tumor-to-liver and spleen-to-liver ratios are similar for both membrane compositions, suggesting a primary role for the liposome's size, compared to the liposome's surface charge. Conclusions:The findings of this study suggest that large targeted liposomes administered i.p. could be a potent drug-delivery strategy for locoregional therapy of i.p. micrometastatic tumors.

KW - Intraperitoneal therapy

KW - Large liposomes

KW - Ovarian cancer

KW - Targeted liposomes

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=78049465208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049465208&partnerID=8YFLogxK

U2 - 10.3109/08982100903544185

DO - 10.3109/08982100903544185

M3 - Article

VL - 20

SP - 330

EP - 340

JO - Journal of Liposome Research

JF - Journal of Liposome Research

SN - 0898-2104

IS - 4

ER -